You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 瑞普生物(300119.SZ)漲逾6% 相關產品取得獸藥產品批准文號
格隆匯 09-25 10:14
格隆匯9月25日丨瑞普生物(300119.SZ)快速拉昇,現報21.33元,漲幅6.3%,最新總市值86.3億。公司24日公告稱,控股子公司華南生物重組禽流感病毒(H5+H7)三價滅活疫苗獲得由農業農村部核發的獸藥產品批准文號。產品的成功研製不僅能有效解決當前H5、H7亞型高致病性禽流感病毒的防控難題,為我國養禽業的健康發展提供有效的技術支撐,而且作為公司政府招標和市場營銷體系中的重要產品,也將促進公司家禽產品市場佔有率提升。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account